



## Nanomedicine Progress in Tumor Treatment

Guest Editor:

**Dr. Giacomo Reina**

Graduate School of Human and  
Environmental Studies, Kyoto  
University, Sakyo-ku, Kyoto 606-  
8501, Japan

Deadline for manuscript  
submissions:

**closed (20 February 2023)**

### Message from the Guest Editor

In the era of precision medicine, hard nanomaterials (HNMs) have emerged as crucial allies for the treatment of different types of cancer. Due to their nanoscopic dimension, HNMs can preferentially accumulate in the tumoral tissues as an extensively useful for drug or gene delivery. Additionally, depending on size, shape, composition, and functionalization, HNMs have been used for active tumor targeting and cancer imaging, or as nano-photosensitizers. More recently, the interaction of HNMs with the immune system has been investigated, showing that these nanosized objects can induce a positive immunological response. Developing of more complex architectures for the precise design of multifunctional nanomaterials is highly desirable for cancer treatment. Additionally, understanding the complexity of HNMs interaction within the biological environment, their targeting and pharmacological efficacy, and their biosafety will support the development of the next generation of strategies to significantly improve the antitumor activity.

This Special Issue aims to highlight recent advances in HNMs application in cancer treatment.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)